Bris­tol My­er­s' Caforio: CELMoDs have po­ten­tial to re­place Revlim­id and Po­m­a­lyst as block­busters start to lose ex­clu­siv­i­ty

Star­ing down the in­evitable loss of ex­clu­siv­i­ty over the next few years for Bris­tol My­ers Squibb’s block­buster mul­ti­ple myelo­ma drugs Revlim­id and Po­m­a­lyst, the Big Phar­ma’s ex­ec crew reaf­firmed on a Q4 call to­day that they just might have po­ten­tial suc­ces­sors to take their place. The two drugs that made Cel­gene rich and brought more rev­enue to Bris­tol My­ers made a com­bined $15 bil­lion or so last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER